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Glycated haemoglobin for the  
diagnosis of diabetes 
SUMMARY
The development of specific diabetes complications correlates with glycated haemoglobin 
(HbA1c), the most accepted measure of chronic glycaemia.
An HbA1c of 48 mmol/mol (6.5%) or greater has now been recommended in Australia for 
diagnosis of type 2 diabetes. 
The HbA1c test should greatly simplify the diagnostic pathway, negating the need for oral glucose 
tolerance tests in the majority of patients. However, improved performance and precision of the 
assay with its standardisation across Australia is required. 
Many clinical situations can impact on the HbA1c assay and the clinician needs to be aware of 
these if it is to be used appropriately for diagnosis. 
ex vivo falls quickly even when collected in a fluoride 
tube, and the inter-laboratory results vary by at least 
14% in a third of cases.6,7 
With the oral glucose tolerance test, the patient 
should be on an appropriate diet for three days 
beforehand and have had a satisfactory period of 
overnight fasting. The test is time consuming to 
perform, taking at least two hours and involving three 
blood glucose samples. It is also labour intensive for 
pathology laboratories. The test is poorly tolerated by 
a significant number of people, with nausea, vomiting, 
delayed gastric emptying and issues of venous access 
all contributing to an invalid test. It often needs to be 
repeated and has poor patient compliance. A recent 
study from the Flinders Medical Centre in South 
Australia showed that only 27% of patients identified 
on admission as potentially having diabetes presented 
for a diagnostic oral glucose tolerance test despite 
repeated contact.8 
Glycated haemoglobin (HbA1c) 
testing
Glycated haemoglobin (HbA1c) is produced by the 
non-enzymatic glycation of haemoglobin. The degree 
of glycation reflects the mean plasma glucose over 
the life of the red blood cell (approximately three 
months). Testing HbA1c is attractive as it measures 
chronic glycaemia rather than instantaneous blood 
glucose. It has been used as an objective marker 
of average glycaemic control for many years and 
has an accepted place in the monitoring of patients 
with diabetes. A review of eight studies conducted 
between 1988 and 2004 reported that HbA1c 
concentrations above 48 mmol/mol (6.5%) were at 
Introduction
Diabetes results from elevated blood glucose and 
its diagnosis has traditionally been estabished by 
measuring blood glucose. The current blood glucose 
criteria used for diagnosis are associated with an 
increased risk of diabetes-related complications. 
The major disease burden of type 2 diabetes is from 
macrovascular disease. There is a strong relationship 
between elevated blood glucose and coronary 
heart disease. Unfortunately, there is no threshold 
of blood glucose concentration associated with 
the development of coronary heart disease so the 
diagnosis cannot be related to macrovascular risk.1 
In contrast, there is a clear glycaemic threshold for 
the development of microvascular complications, 
particularly diabetic retinopathy. There are also 
excellent outcome data showing that glucose-
lowering therapy effectively prevents these 
complications.2 The modern diagnosis of diabetes 
has therefore been based on blood glucose criteria 
associated with the development of retinopathy.3,4 
Over time, these blood glucose criteria have 
changed as the understanding of their relationship to 
retinopathy has improved.5 
Blood glucose testing
The reliability of a blood glucose test performed in 
a laboratory is taken for granted by most medical 
practitioners. However, there are major practical 
problems with the fasting blood glucose and the oral 
glucose tolerance tests. 
The day to day variation of blood glucose is 
considerable. The concentration of blood glucose  
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a transfusion, the test should be delayed for three 
months, until the HbA1c measurement will be valid. 
Recommendations
Along with other international organisations,15,16 the 
Australian Diabetes Society has recommended that an 
HbA1c of 48 mmol/mol (6.5%) can be used to establish 
the diagnosis.13 This recommendation is to be used in 
conjunction with National Health and Medical Research 
Council guidelines for the management of type 2 
diabetes.17 In the absence of symptoms, a second 
elevated HbA1c is necessary to confirm the diagnosis.
Currently in Australia, an HbA1c test can only be 
reimbursed by Medicare in patients with established 
diabetes. The Australian Diabetes Society has 
submitted a proposal to Medicare to accept the 
measurement of HbA1c for diagnosis but this proposal 
is still under consideration. 
Discrepancies between blood glucose 
and HbA1c tests
HbA1c is a measure of chronic glycaemia whereas blood 
glucose tests are acute measurements at one point  
in time. These tests will identify different populations  
of patients. Most people with elevated blood glucose  
will have a raised HbA1c. However, some patients with  
a minor elevation on the fasting blood glucose or oral  
glucose tolerance tests will have an HbA1c of less than 
48 mmol/mol (6.5%) (the diagnostic threshold). How  
does a practitioner resolve this discrepancy? Usually,  
the blood glucose concentrations are only minimally  
raised in these patients and the HbA1c result implies  
that they are at minimal or no risk of developing  
microvascular complications.9-11 Although their blood  
glucose results are consistent with the biochemical  
diagnosis, they do not have chronic hyperglycaemia  
which is associated with an increased risk of developing 
microvascular complications. This means they do  
not have clinically relevant diabetes. These patients  
should still be assessed for their risk of macrovascular  
diseases, and their blood pressure and lipids managed  
appropriately. The test should be repeated.
Pregnancy
HbA1c cannot be used to diagnose diabetes in 
pregnancy. If true diabetes in pregnancy is suspected, 
blood glucose criteria must be used.
Conclusion
The acceptance of HbA1c testing will provide an 
additional tool to assist in the early diagnosis of 
diabetes. But it should not be the only tool. There 
remains a very important role for blood glucose testing, 
and the medical practitioner needs to be aware of the 
least as strongly correlated with the development of 
diabetic retinopathy as blood glucose concentrations.9 
HbA1c is also associated with macrovascular outcomes 
and mortality, although there is no threshold below 
which there is no risk.1,10,11 
HbA1c testing provides significant practical 
advantages over blood glucose measurement. It 
can be performed at any time of the day and does 
not require any special pre-test preparation by the 
patient. The blood sample is stable once collected –  
essentially in the same tube used for a full blood 
count. When access to an appropriate laboratory is 
limited, the test can be performed using a point-of-
care testing machine. This may be particularly useful 
in rural and remote areas.  
Standardisation
HbA1c testing must be reliable and consistent 
across Australia. The US National Glycohemoglobin 
Standardization Program has driven improvements 
in assays.12 The variability of different tests for 
HbA1c within Australia is now acceptable. In a recent 
Australian study, whole blood samples were sent to 
more than 200 laboratories for testing. More than 
90% of HbA1c results fell within 6% of the median.13 
Further improvements in standardisation should be 
achieved following the development of a national 
quality control program by the Royal College of 
Pathologists of Australasia, the Australian Association 
of Clinical Biochemists and the Australian Diabetes 
Society. Standardisation and calibration are extremely 
important if point-of-care testing is used for 
establishing the diagnosis.
Limitations 
There are a number of clinical conditions which may 
affect the accuracy of the test, resulting in falsely 
high or low readings. The major concern is of a 
falsely low HbA1c result being interpreted as being 
normal in a patient with true diabetes. This may 
delay diagnosis, with the potential for significant 
long-term consequences. It is very important that 
clinicians are fully aware of the test’s limitations. Any 
condition that leads to a shortened red cell survival 
time can interfere with the HbA1c assay. This includes 
the haemoglobinopathies, therapeutic venesection, 
anaemia, haemolysis, recent transfusion, and chronic 
renal failure. If any of these conditions are thought to 
exist, the diagnosis should be made on measures of 
blood glucose.6,7,14 The effect of haemoglobinopathies 
is complex, varying with the type of 
haemoglobinopathy, the instrument and the method 
used in the laboratory. If suspected, discuss this 
issue with your local chemical pathology laboratory. 
If a patient has had a therapeutic venesection or 
100
ARTICLE
Full text free online at www.australianprescriber.com
VOLUME 37 : NUMBER 3 : JUNE 2014
DIAGNOSTIC TESTS Glycated haemoglobin for the diagnosis of diabetes 
Conflict of interest: none declared
The author wishes to acknowledge the input of the HbA1c 
committee of the Australian Diabetes Society which 
developed the recommendations for the use of glycated 
haemoglobin for diagnosis in Australia. 
benefits and limitations of both strategies. However, 
the HbA1c test does overcome many of the practical 
problems associated with the fasting blood glucose or 
oral glucose tolerance tests and its correct use should 
enhance the early diagnosis of type 2 diabetes. 
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New drugs
continuous activation of the kinase which promotes 
cell proliferation and inhibits apoptosis. Up to 5% 
of people with non-small cell lung cancer will have 
mutated ALK. These are mainly adenocarcinomas and 
are more likely to occur in non-smokers.
Following an oral dose, peak concentrations are 
reached after 4–6 hours. Steady state is reached 
after 15 days with twice-daily dosing. After extensive 
metabolism in the liver, most of the dose is eliminated 
in the faeces (63%) and urine (22%). The terminal 
half-life is 42 hours. Drug concentrations are likely to 
increase in hepatic impairment so caution is urged in 
these patients. Dose reduction is needed in people 
Crizotinib
Approved indication: non-small cell lung cancer
Xalkori (Pfizer)
200 mg and 250 mg capsules
Australian Medicines Handbook section 14.2.3
Along with erlotinib (Aust Prescr 2006;29:53-5) 
and gefitinib (Aust Prescr 2003;26:94-5), crizotinib 
is an oral tyrosine kinase inhibitor for non-small 
cell lung cancer – it is indicated for people with 
anaplastic lymphoma kinase (ALK)-positive advanced 
disease. Rearrangements in this gene lead to 
